Johnson & Johnson announces healthy Q2 results

News

Johnson & Johnson has announced sales of $17.9 billion for the second quarter of 2013, which is an increase of 8.5% compared with the second quarter of 2012.

The acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business, had made some impact on sales. Aside from this impact, worldwide operational sales growth was 5.6%.

"Our strong second-quarter results reflect the progress we've made against our near-term priorities of delivering on our financial commitments, restoring a reliable supply of over-the-counter products to consumers, continuing the successful integration of Synthes and building on the momentum in our pharmaceutical business. Our talented colleagues at Johnson & Johnson continue to bring meaningful innovations to patients and consumers around the world and have positioned us well to deliver sustainable growth."

Alex Gorsky, Chairman and Chief Executive Officer